INMD250117C27500
- 0.05
- 0.000.00%
InMode Newsroom
InMode Faces Macroeconomic Challenges and Manufacturing Disruptions, Leading to Hold Rating
Barclays Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $26
Express News | Inmode Ltd : Jefferies Cuts Target Price to $16 From $18
InMode Is Maintained at Overweight by Barclays
InMode Price Target Cut to $26.00/Share From $27.00 by Barclays
InMode Analyst Ratings
Barclays Maintains InMode(INMD.US) With Buy Rating, Cuts Target Price to $26
Needham Maintains InMode(INMD.US) With Hold Rating
Needham Remains a Hold on InMode (INMD)
BTIG Maintains InMode(INMD.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: InMode (INMD) and Sana Biotechnology (SANA)
InMode Lowers 2024 Revenue Guidance; Sets 2025 Revenue Outlook; Shares Slump Pre-Bell
InMode Sees FY24 Adjusted Gross Margin 80%-81%
Express News | InMode Cuts FY24 Revenue Outlook From $410M - $420M To $394M - $394.5M, Est $411.188M
Express News | InMode Expects Q4 Revenue Of $97.0M-$97.5M (Est $114.22M); Preliminary Results Reflect Stronger-than-Expected Headwinds In Aesthetics Industry
InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M
Is InMode Ltd.'s (NASDAQ:INMD) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
With 57% Institutional Ownership, InMode Ltd. (NASDAQ:INMD) Is a Favorite Amongst the Big Guns
Is There An Opportunity With InMode Ltd.'s (NASDAQ:INMD) 49% Undervaluation?
Why Is InMode Ltd. (INMD) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now?